【摘要】 目的探讨阿托伐他汀对老年高脂血症患者血清高敏C反应蛋白(hs-CRP)的影响、调脂疗效及其安全性。方法检测40例使用阿托伐他汀治疗前,以及治疗1、3月后的老年高脂血症患者血清hs-CRP水平、血脂水平、肝肾功能和肌溶解反应。40例年龄与性别相匹配的健康者作为正常对照。结果高脂血症组血清hs-CRP水平高于对照组(P<0.01);高脂血症组治疗1、3月后,hs-CRP、总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白胆固醇(LDL-C)水平均明显下降(P<0.01),高密度脂蛋白胆固醇(HDL-C)水平明显上升(P<0.01),其中治疗1月后治疗组hs-CRP水平下降33%,TC水平下降32.19%,TG水平下降12.74%,LDL-C水平下降36.02%,HDL-C水平上升8.06%;治疗3月后治疗组hs-CRP、TC和LDL-C水平仍明显下降,与治疗1月后比较,差异有显著性(P均<0.01),HDL-C水平稍上升,TG水平稍下降,但与治疗1月后比较,差异无显著性(P>0.05);而丙氨酸氨基转移酶(ALT)、尿素氮(BUN)、肌酐(Cr)和肌酸磷酸激酶(CK)水平均无明显变化(P>0.05)。结论应用阿托伐他汀治疗老年高脂血症患者,除调脂效果明显外,尚能显著降低血清hs-CRP水平,并且无明显肝肾功能损害和肌溶解等不良反应。更多还原

【Abstract】 Objective To observe the efficacy and safety of atorvastatin on decreasing high-sensitivity C-reactive protein(hs-CRP) and blood lipid in elderly patients with primary hyperlipidemia.Methods Forty elderly patients with primary hyperlipidemia(treatment group) received atorvastatin(lipitor) for 3 months.The levels of hs-CRP,total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesteorl(LDL-C),high density lipoprotein cholesterol(HDL-C),serum alanine aminotransferase(ALT),blood urea nitrogen(BUN),serum creatinine(Cr)and creatine kinase(CK) were detected before treatment and at the first month and third month of treatment,and were compared with those in 40 healthy elderly people(control group).Results The level of hs-CRP in treatment group before treatment were significantly higher than that in control group(P<0.01).After treatment of atorvastatin for 1 or 3 months,the levels of hs-CRP,TC,TG and LDL-C were significantly lower in treatment group than those in control group(P<0.01).After 1 month of treatment of atorvastatin,the levels of hs-CRP,TC,TG and LDL-C were decreased by 33%,32.19%,12.74% and 36.02% respectively(P<0.01),and the level of HDL-C was increased by 8.06%(P<0.01).After 3 months of treatment of atorvastatin,the levels of hs-CRP,TC and LDL-C were significantly lower than those after 1 month(P<0.01),but the increase of HDL-C and the decrease of TG were not statistically significant(P>0.05).After treatment of atorvastatin for 1 and 3 months,the levels of ALT,BUN,Cr and CK remained unchanged(P>0.05).Conclusions Treatment of atorvastatin in elderly patients with primary hyperlipidemia can decrease the levels of TC,TG,LDL-C and hs-CRP significantly,and increase the level of HDL-C significantly.The adverse reactions about liver functional lesion,renal functional lesion or rhabdomyolysis of atorvastatin do not appear.Treatment of atorvastatin for elderly patients with primary hyperlipidemia can prevent and treat atherosclerosis.更多还原